Work

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Year: 2023

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2023-178645

Authors: Gabriela S. Hobbs, Haesook T. Kim, Suzanne O'Connor, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Areej El-Jawahri, Steven McAfee, Jessica Hem, Patricia Lozano, Jonas S. Jutzi, Ann Mullally, Yi-Bin Chen, Zachariah Defilipp

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Washington University in St. Louis, Memorial Sloan Kettering Cancer Center, The Ohio State University Wexner Medical Center, Brigham and Women's Hospital, Harvard University, Albert Einstein College of Medicine

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389246663

Cites:

Cited by: 11

Related to: 10